Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 19/20 | 0.82 |
| ▸ | EED | O75530 | 11/20 | 0.73 |
| ▸ | RBBP4 | Q09028 | 11/20 | 0.73 |
| ▸ | SUZ12 | Q15022 | 11/20 | 0.73 |
| ▸ | AEBP2 | Q6ZN18 | 11/20 | 0.73 |
| ▸ | EZH1 | Q92800 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24884856 | 0.88 | EZH2 (0.77) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL13277789 | 0.84 | EZH2 (1.00) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL29613480 | 0.84 | EZH2 (1.00) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL13467751 | 0.81 | EZH2 (1.00) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL19503754 | 0.81 | EZH2 (0.56) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL20549585 | 0.81 | EZH2 (0.79) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL26535690 | 0.81 | EZH2 (0.79) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL18428818 | 0.80 | EZH2 (0.84) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL29180266 | 0.80 | EZH2 (0.72) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL13280106 | 0.80 | EZH2 (0.86) | EZH2EEDRBBP4SUZ12AEBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | EZH2 377/4885EED 346/4885RBBP4 29/4885 |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | CRBN, MDM2, VHL | EZH2 377/4885EED 346/4885RBBP4 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.